Schrodinger, Inc. (SDGR)
Nasdaq: SDGR · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2010
Who owns Schrodinger, Inc.
As filed with the SECHolders of 5% or more
3
Blackrock, Inc. holds 12.7% of Common Stock, as its SCHEDULE 13G/A filed Jul 18, 2025 says.
Directors and officers
20
report now, of 27 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 18, 2025 · Common Stock
Rubric Capital Management LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.01 par value per share · 6.47% in Feb 13, 2026
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
Sumitomo Mitsui Trust Group, Inc.
SCHEDULE 13G/A · filed Apr 30, 2026 · Common stock, par value $0.01 per share · reported falling below 5%, from 7.1% in Oct 27, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What SDGR reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Structure Therapeutics
An investee · investee · invested in, named in the 10-K filed Feb 25, 2026
7 subsidiaries in 7 countries, from the list filed with the 10-K filed Feb 25, 2026.
Insider tradesForm 4
26sales
0purchases
26sales on a scheduled plan
7people selling
$4.2Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 38 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Farid Ramy | President & CEO | 4 | $1.2M | 4 | 0 | $0 |
| Tran Yvonne | EVP, CLO & CPO | 6 | $1.1M | 6 | 0 | $0 |
| Akinsanya Karen | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | 4 | $1.0M | 4 | 0 | $0 |
| Abel Robert Lorne | See Remarks | 4 | $800,000 | 4 | 0 | $0 |
| Jain Rachit | EVP & CFO | 3 | $0 | 3 | 0 | $0 |
| Lorton Kenneth Patrick | EVP, CTO & COO, Software | 2 | $0 | 2 | 0 | $0 |
| Herman Jenny | CAO | 3 | $0 | 3 | 0 | $0 |